Oncology (cancer) diagnostics company NeoGenomics (NASDAQ: NEO) reported Q4 CY2025 results exceeding the market’s revenue expectations, with sales up 10.6% year on year to $190.2 million. The company expects the full year’s revenue to be around $797 million, close to analysts’ estimates. Its non-GAAP profit of $0.06 per share was $0.02 above analysts’ consensus estimates.

Is now the time to buy NEO? Find out in our full research report (it’s free for active Edge members).

StockStory’s Take

NeoGenomics’ fourth quarter results were met with a negative market reaction, despite revenue and non-GAAP earnings per share surpassing Wall Street’s expectations. Management attributed the quarter’s performance to continued growth in next-generation sequencing (NGS) test volumes, robust adoption of new products, and a deliberate shift away from lower-value, high-volume testing. CEO Anthony Zook noted, “Our clinical business continued its robust growth with revenue increasing 16% year over year,” highlighting the company’s ability to drive higher average revenue per test through targeted commercial execution.

Looking to the year ahead, NeoGenomics’ forward guidance reflects both opportunity and caution as the company invests in expanding its test menu and commercial reach. Management expects modest revenue contributions from the full clinical launch of RADAR ST and continued expansion of the PANTRASER portfolio, while acknowledging that reimbursement decisions and adoption rates will shape results. CFO Abhishek Jain emphasized, “We will continue to take a balanced approach to investments, strategically increasing sales and marketing and R&D spend for new product initiative and clinical programs.”

Key Insights from Management’s Remarks

Management credited the quarter’s growth to the success of its NGS product suite, increased penetration among community oncologists, and operational efficiencies gained through targeted investments and portfolio optimization.

• NGS growth outpaces market: NeoGenomics reported 23% year-over-year NGS revenue growth, surpassing the broader market and driven by uptake of five new NGS products launched since 2023.
• Commercial channel expansion: The company expanded its oncology sales specialists by 35 members in 2025, resulting in increased test adoption and a higher percentage of oncologists ordering multiple NeoGenomics tests.
• Portfolio optimization boosts margins: Management intentionally exited low-value, high-volume testing contracts, focusing resources on higher-margin tests and products, which contributed to sequential improvement in average revenue per test.
• Pathline acquisition synergies: The acquisition of Pathline strengthened NeoGenomics’ presence in the Northeast U.S. and is expected to become accretive to profitability as operational efficiencies are realized.
• RADAR ST launch and new indications: The company prepared for the full clinical launch of its RADAR ST minimal residual disease (MRD) test, targeting initial indications in head and neck and breast cancers, with future revenue growth dependent on securing additional reimbursement approvals.

Drivers of Future Performance

NeoGenomics expects future performance to be shaped by new product launches, expansion into higher-value testing, and ongoing margin improvement efforts.

• RADAR ST commercialization: Management anticipates modest initial revenues from RADAR ST in approved indications, with broader adoption and reimbursement decisions for new cancer types expected to significantly expand the addressable market in future years.
• NGS and PANTRASER expansion: Continued growth in NGS and the PANTRASER portfolio, particularly as liquid biopsy (LBX) and Pro versions gain traction, are positioned as primary growth drivers, with success hinging on market adoption and positive reimbursement outcomes.
• Margin and operational efficiency focus: The company is investing in laboratory information management system (LIMS) integration and workflow automation, aiming for approximately 100 basis points of gross margin improvement in 2026 and further gains as efficiencies are realized.

Catalysts in Upcoming Quarters

In coming quarters, the StockStory team will watch (1) the pace of adoption for RADAR ST and the timing of reimbursement approvals for new indications, (2) sustained NGS and PANTRASER portfolio momentum as new products reach the market, and (3) progress on LIMS integration and operational efficiencies. Continued success in shifting the product mix toward higher-value tests and securing favorable coverage decisions will be critical for sustained growth.

NeoGenomics currently trades at $11.40, in line with $11.38 just before the earnings. Is there an opportunity in the stock?Find out in our full research report (it’s free).

High Quality Stocks for All Market Conditions

Your portfolio can’t afford to be based on yesterday’s story. The risk in a handful of heavily crowded stocks is rising daily.

The names generating the next wave of massive growth are right here in our Top 5 Strong Momentum Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 244% over the last five years (as of June 30, 2025).

Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today.